ScienceDirect - Peptides : Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: Combined anorectic effects of Y2 and Y4 receptor-selective agonists

Peptides
Volume 28, Issue 2, February 2007, Pages 235-240
NPY AND COHORTS IN HUMAN DISEASE, Proceedings of the 8th International NPY meeting 2006

Font Size:

Abstract - selected

Article Toolbox

E-mail Article

Add to my Quick Links

Bookmark and share in 2collab (opens in new window)

Request permission to reuse this article

Cited By in Scopus (2)

Related Articles in ScienceDirect

Obesity--is it all in the mind?
The Lancet Neurology

Short-term oral oleoyl-estrone decreases the expression...
Regulatory Peptides

Paraventricular nucleus injections of peptide YY and ne...
Peptides

Robust feeding following central administration of neur...
Peptides

Role of neuropeptides in appetite regulation and obesit...
Neuropeptides

View More Related Articles

View Record in Scopus

doi:10.1016/j.peptides.2006.08.041

Neuropeptide Y (NPY) Y₂ receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: Combined anorectic effects of Y₂ and Y₄ receptor-selective agonists

References and further reading may be available for this article. To view references and further reading you must purchase this article.

Ambikaipakan Balasubramaniam^a^,^b^,^,, Rashika Joshi^a^,^b, Chunhua Su^a^,^b, Lou Ann Friend^a^,^b and J. Howard James^a^,^b

^aDepartment of Surgery, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA

^bShriners Hospital for Children, Cincinnati, OH 45229, USA

Received 8 March 2006;

accepted 20 August 2006.

Available online 3 January 2007.

Abstract

Peripheral administration of the endogenous Y₂ and Y₄ receptor selective agonists, PYY(3–36) and PP, have been shown to inhibit food intake and body weight gain in rodents, and to reduce appetite and caloric intake in humans. We have previously developed a long-acting, potent and highly selective Y₂ receptor selective agonist, N-α-Ac-[Nle^24,28, Trp³⁰, Nva³¹, Ψ^35–36]PYY(22–36)-NH₂ (BT-48). BT-48 (ip) dose-dependently inhibited ad lib food intake and also decreased the respiratory quotient in mice during both the light and dark periods. The latter observation is indicative of enhanced fat metabolism. Moreover, BT-48 also inhibited food intake in fasted mice. Combined ip administration of BT-48 (50 nmol/mouse) with a highly potent and selective Y₄ anorectic peptide, BVD-74D (50 nmol/mouse), resulted in a powerful and long lasting inhibitory effect on food intake. As expected, this inhibitory effect on food intake was nearly double that exhibited by either peptide (50 nmol/mouse) alone. In summary, BT-48, unlike PYY(3–36), exhibits little or no affinity to other “Y” receptors, and may therefore have a better clinical potential than PYY(3–36) for control of food intake. Moreover, it appears that treatment with a combination of Y₂ and Y₄ receptor selective agonists may constitute a more powerful approach to control food intake than treatment with either of these agonists alone.